目的:观察小青龙汤加减治疗小儿支原体肺炎的临床疗效。方法:将92例小儿支原体肺炎患者按照随机数字表法分为对照组和研究组,每组46例。对照组给予常规治疗,肺炎急性期使用布地奈德雾化液雾化治疗,肺炎症状缓解期使用孟鲁司特钠咀嚼片...目的:观察小青龙汤加减治疗小儿支原体肺炎的临床疗效。方法:将92例小儿支原体肺炎患者按照随机数字表法分为对照组和研究组,每组46例。对照组给予常规治疗,肺炎急性期使用布地奈德雾化液雾化治疗,肺炎症状缓解期使用孟鲁司特钠咀嚼片口服治疗。研究组在对照组治疗的基础上给予小青龙汤加减治疗。观察两组患者临床疗效、肺功能[用力肺活量(forced vital capacity,FVC)、最大呼气流速(peak expiratory flow,PEF)以及第1秒用力呼气容积(forced expiratory volume in the first second,FEV1)]、气道高反应性、复发情况,并检测血清白细胞介素(interleukin,IL)-4、IL-5与外周血嗜酸性粒细胞(eosinophil,EOS)水平。结果:研究组有效率91.30%,对照组有效率为76.09%,研究组有效率高于对照组,差异有统计学意义(P<0.05)。研究组治疗后FVC、PEF、FEV1水平高于对照组,差异有统计学意义(P<0.05)。研究组治疗后最小诱发累积量、促使气道阻力增加至基础值的135%所需要的组胺累积剂量高于对照组,差异有统计学意义(P<0.05)。研究组治疗后血清IL-4、IL-5与外周血EOS低于对照组,差异有统计学意义(P<0.05)。研究组复发率为19.05%(8/42),对照组复发率为42.86%(15/35),研究组复发率低于对照组,差异有统计学意义(P<0.05)。结论:小青龙汤加减治疗治疗小儿支原体肺炎,能改善患者肺功能,减轻患儿气道高反应性,调节血清IL-4、IL-5水平以及外周血EOS水平,降低复发率。展开更多
The Maastricht IV/Florence Consensus Report and the Second Asia-Pacific Consensus Guidelines strongly recommend eradication of Helicobacter pylori(H.pylori)in patients with previous gastric neoplasia who have undergon...The Maastricht IV/Florence Consensus Report and the Second Asia-Pacific Consensus Guidelines strongly recommend eradication of Helicobacter pylori(H.pylori)in patients with previous gastric neoplasia who have undergone gastric surgery.However,the guidelines do not mention optimal timing,eradication regimens,diagnostic tools,and follow-up strategies for patients undergoing gastrectomy and do not indicate if eradication of H.pylori reduces the risk of marginal ulcer or stump cancer in the residual stomach after gastrectomy.The purpose of this review is to provide an update which may help physicians to properly manage H.pylori infection in patients who have undergone gastric surgery.This review focuses on(1)the microenvironment change in the stomach after gastrectomy;(2)the phenomenon of spontaneous clearance of H.pylori after gastrectomy;(3)the effects of H.pylori on gastric atrophy and intestinal metaplasia after gastrectomy;(4)incidence and clinical features of ulcers developing after gastrectomy;(5)does eradication of H.pylori reduce the risk of gastric stump cancer in the residual stomach?(6)does eradication of H.pylori reduce the risk of secondary metachronous gastric cancer in the residual stomach?and(7)optimal timing and regimens for H.pylori eradication,diagnostic tools and follow-up strategies for patients undergoing gastrectomy.展开更多
文摘目的:观察小青龙汤加减治疗小儿支原体肺炎的临床疗效。方法:将92例小儿支原体肺炎患者按照随机数字表法分为对照组和研究组,每组46例。对照组给予常规治疗,肺炎急性期使用布地奈德雾化液雾化治疗,肺炎症状缓解期使用孟鲁司特钠咀嚼片口服治疗。研究组在对照组治疗的基础上给予小青龙汤加减治疗。观察两组患者临床疗效、肺功能[用力肺活量(forced vital capacity,FVC)、最大呼气流速(peak expiratory flow,PEF)以及第1秒用力呼气容积(forced expiratory volume in the first second,FEV1)]、气道高反应性、复发情况,并检测血清白细胞介素(interleukin,IL)-4、IL-5与外周血嗜酸性粒细胞(eosinophil,EOS)水平。结果:研究组有效率91.30%,对照组有效率为76.09%,研究组有效率高于对照组,差异有统计学意义(P<0.05)。研究组治疗后FVC、PEF、FEV1水平高于对照组,差异有统计学意义(P<0.05)。研究组治疗后最小诱发累积量、促使气道阻力增加至基础值的135%所需要的组胺累积剂量高于对照组,差异有统计学意义(P<0.05)。研究组治疗后血清IL-4、IL-5与外周血EOS低于对照组,差异有统计学意义(P<0.05)。研究组复发率为19.05%(8/42),对照组复发率为42.86%(15/35),研究组复发率低于对照组,差异有统计学意义(P<0.05)。结论:小青龙汤加减治疗治疗小儿支原体肺炎,能改善患者肺功能,减轻患儿气道高反应性,调节血清IL-4、IL-5水平以及外周血EOS水平,降低复发率。
文摘The Maastricht IV/Florence Consensus Report and the Second Asia-Pacific Consensus Guidelines strongly recommend eradication of Helicobacter pylori(H.pylori)in patients with previous gastric neoplasia who have undergone gastric surgery.However,the guidelines do not mention optimal timing,eradication regimens,diagnostic tools,and follow-up strategies for patients undergoing gastrectomy and do not indicate if eradication of H.pylori reduces the risk of marginal ulcer or stump cancer in the residual stomach after gastrectomy.The purpose of this review is to provide an update which may help physicians to properly manage H.pylori infection in patients who have undergone gastric surgery.This review focuses on(1)the microenvironment change in the stomach after gastrectomy;(2)the phenomenon of spontaneous clearance of H.pylori after gastrectomy;(3)the effects of H.pylori on gastric atrophy and intestinal metaplasia after gastrectomy;(4)incidence and clinical features of ulcers developing after gastrectomy;(5)does eradication of H.pylori reduce the risk of gastric stump cancer in the residual stomach?(6)does eradication of H.pylori reduce the risk of secondary metachronous gastric cancer in the residual stomach?and(7)optimal timing and regimens for H.pylori eradication,diagnostic tools and follow-up strategies for patients undergoing gastrectomy.
